Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Riverfolkon Jul 07, 2022 2:01pm
308 Views
Post# 34809033

Globe says Arch seen having "blockbuster potential"

Globe says Arch seen having "blockbuster potential"The Globe and Mail reports in its Thursday edition that iA Capital analyst Chelsea Stellick says Arch Biopartners possesses "blockbuster potential to establish a new standard of care" for preventing and treating organ damage with its lead drug candidate Metablok. The Globe's David Leeder writes that Ms. Stellick rates Arch "speculative buy" in new coverage. She set a share target of $6. The Globe notes that Ms. Stellick is the lone analyst covering the stock. Ms. Stellick says in a note: "Because so many diseases or injuries cause inflammation in the lungs, liver, or kidneys, there are many possible permutations for Arch's path to its first product approval. Acute kidney injury (AKI) is the company's lead indication, which affects over six million people annually in the U.S. The optionality of holding a suite of drug candidates applicable to multiple indications will allow Arch to pursue the optimal combination of clinical trials to identify the best niches for DPEP1 inhibition given market size, capital, time, and regulatory considerations. For added diversification via possible future partnerships, developments or monetization opportunities, Arch also holds a small portfolio of unrelated early stage assets."
<< Previous
Bullboard Posts
Next >>